Omecamtiv mecarbil: Completed Phase IIb enrollment

Cytokinetics said it and Amgen completed enrollment in the double-blind, placebo-controlled, international Phase IIb ATOMIC-AHF trial evaluating 3 doses of IV omecamtiv mecarbil for 48 hours in about ...